GHB-ACTION investigates interactions between small molecules and the important brain enzyme CaMKII
The mission of Molecular Neuroprotection is to:
- Develop new neuroprotective principles in neurodegeneration.
- Obtain mechanistic insight into molecular aspects of acute and chronic neurodegeneration.
- Explore the potential for manipulations of cellular or molecular pathways or mechanisms for prevention preventing or regeneration limiting neurodegenerative loss.
- To accomplish our aims, we will focus on emerging or poorly studied pathways in neurons or glial neural cells, including identification of new molecular targets for compound development as research tools or potential therapeutics. We aim to translate these diagnostic and therapeutic tools from bench-to-bedside.
- Radioactive labeling strategies, especially for the PET nuclides carbon-11 and fluorine-18; combinatorial-like PET tracer development
- Tool development to study CNS related pharmacological targets as GPCR´s, ion channels and enzymes
- Bioorthogonal chemistry: Applied radioactive, organic chemistry in living organisms
- Functional selective PET imaging: Is conformational selection the key to biased agonism?
- Targeting Keap1 and NOX2 to inhibit oxidative stress in the brain
- Examination of degeneration assocaited with -synuclein of neurons involved in non-motor symptoms of Parkinson’s Disease
- Alterations in cellular functioning in animal models of Alzheimer’s Disease overexpressing -amyloid
- Medicinal chemistry (drug design, small-molecule synthesis)
- Radiopharmaceutical chemistry (radiolabeling, molecular imaging such as PET and SPECT)
- Radioligand-based methods (in vitro, ex vivo, in vivo)
- Molecular biology and biochemistry (recombinant DNA technology, protein expression, purification, and characterization, MS, LC)
- Structural biology (X-ray and Cryo-EM structure determination, SAXS)
- Computational chemistry (structure-based ligand design and characterization)
- Fragment-based Drug Discovery (fragment-screening and characterization, optimization into leads)
- Molecular pharmacology (in vitro pharmacological assay development, high-throughput screening technology, heterologous, cell lines and primary cell cultures)
- Neurophysiology (neuron, microgliaal and astrocyte culturing, slice electrophysiology, in vivo electrophysiology)
- Animal disease models (Alzheimer’s disease, stroke/TBI)
- Human cell-based disease models (iPSC) (via collaborators)
Dr. Roberta Brambilla, Associate Professor, Department of Neurologic Surgery, The Miami Project to Cure Paralysis, Miami, Florida
Dr. Kate Lykke Lambertsen, Professor, MSO, IMM-Neurobiologisk Forskning, Syddansk Univesitet.
Dr. Gitte Moos Knudsen: Chair, Professor, MD, DMSc Dept. Neurology and Neurobiology Research Unit Copenhagen University Hospital, Rigshospitalet,
Dr. Stina Syvänen: Senior lecturer/Associate Professor at Uppsala University, Department of Public Health and Caring Sciences, Geriatrics; Molecular Geriatrics / Rudbeck laboratory.
Dr. Bert Windhorst: Full Professor, Amsterdam UMC, Radiology and nuclear medicine, Amsterdam Neuroscience.
Dr. Andreas Maurer: Research Group Leader Imaging Probe Development, University of Tübingen, Werner Siemens Imaging Center.
|Anders Bach||Associate professor|
|Anders Skov Kristensen||Associate professor|
|Annette Eva Langkilde||Associate professor|
|Bente Frølund||Professor with special responsibilities|
|Jette Sandholm Jensen Kastrup||Professor|
|Karla Andrea Frydenvang||Associate professor|
|Kristi Anne Kohlmeier||Associate professor|
|Lasse Kristoffer Bak||Associate professor|
|Linda Grønborg Dorvil||Assistant professor|
|Maria Elena Klibo Lie||Postdoc|
|Matthias Manfred Herth||Associate professor|
|Miriam Grønlund Pedersen||Assistant professor|
|Petrine Wellendorph||Associate professor|
|Uffe Kristiansen||Associate professor|
|Umberto Maria Battisti||Assistant professor|